{
    "organizations": [],
    "uuid": "347e17ce70f39d13ef2c0b3bdacc94a0158a6069",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-uniqure-says-as-of-dec-31-co-had-1/brief-uniqure-says-as-of-dec-31-co-had-159-mln-in-cash-cash-equivalents-idUSASB0C01R",
    "ord_in_thread": 0,
    "title": "BRIEF-Uniqure Says As Of Dec 31 Co Had $159 Mln In Cash & Cash Equivalents",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Uniqure Nv:\n* UNIQURE PROVIDES YEAR-END 2017 CORPORATE UPDATE AND OUTLINES NEAR-TERM OBJECTIVES TO FURTHER DRIVE SHAREHOLDER VALUE\n* UNIQURE - AS OF DEC 31, 2017, CO HAD ABOUT $159 MILLION IN CASH & CASH EQUIVALENTS; EXPECTS CASH ON HAND SUFFICIENT TO FUND OPERATIONS INTO 2020\n* UNIQURE NV - INTENDS TO INITIATE GLOBAL, PIVOTAL PROGRAM FOR AMT-061 IN HEMOPHILIA B DURING Q3 2018\n* UNIQURE NV - AMENDMENT TO EXISTING INVESTIGATIONAL NEW DRUG (IND) APPLICATION EXPECTED FOR AMT-061 TO BE SUBMITTED TO FDA IN Q1 2018 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)\n ",
    "published": "2018-01-08T20:13:00.000+02:00",
    "crawled": "2018-01-09T17:17:06.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "uniqure",
        "nv",
        "uniqure",
        "provides",
        "corporate",
        "update",
        "outline",
        "objective",
        "drive",
        "shareholder",
        "value",
        "uniqure",
        "dec",
        "co",
        "million",
        "cash",
        "cash",
        "equivalent",
        "expects",
        "cash",
        "hand",
        "sufficient",
        "fund",
        "operation",
        "uniqure",
        "nv",
        "intends",
        "initiate",
        "global",
        "pivotal",
        "program",
        "hemophilia",
        "b",
        "q3",
        "uniqure",
        "nv",
        "amendment",
        "existing",
        "investigational",
        "new",
        "drug",
        "ind",
        "application",
        "expected",
        "submitted",
        "fda",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "bengaluru",
        "newsroom"
    ]
}